Sino Harbour Holdings Group Limited
HHKEX:16630.05
HKD
0.00
(0.00%)
ISIN
BMG8188W1091
CUSIP
G8188W109
Return %
Stock
S&P 500
1Y
-32.35
14.20
3Y
-68.71
81.12
5Y
-62.30
68.34
Capital Structure
CNY
•
in mil. unless spec.Working Capital
CNY
•
in mil. unless spec.Growth Rates
CNY
•
in mil. unless spec.Semi-annual Revenue
CNY
•
in mil. unless spec.Semi-annual Earnings Per Share
CNY
•
in mil. unless spec.Semi-annual Dividends Per Share
CNY
•
in mil. unless spec.Company Description
- CEO
- Lam Ping Wong
- Full Time Employees
- 178
- Sector
- Finance
- Industry
- Real estate development
- Address
- Unit 3505, 35/F, West Tower, Shun Tak Centre, 168-200 Connaught Road Central Hong Kong Hong Kong
- IPO Date
- Jul 22, 2011
- Website
- sinoharbour.com.hk
- Similar Companies
- Business
- Sino Harbour Holdings Group Limited is an investment holding company primarily engaged in property development and diversified businesses. Its core products and services include residential properties, detached housing, apartments, retail, and commercial properties under its Property Development segment. The company also operates through a diversified Other segment which encompasses pharmaceutical inspection services, stem cell business, dental services, consultancy services, and chemistry, manufacturing, and control (CMC) related services. Sino Harbour conducts most of its operations in domestic markets within China and extends to overseas markets. The group’s subsidiaries include Zhejiang IPS Pharmaceutical Technology Co., Ltd., and Pingxiang Ganghua Dentistry Hospital Company Limited, illustrating its commitment to expanding its healthcare-related business sectors. Founded in 2011 and headquartered in Nanchang, China, Sino Harbour has undergone strategic transformation to diversify from solely property development to significant investments in healthcare and life sciences. Recent major developments include expanding its "Big Health" business segment, such as establishing a chain of dental specialty hospitals and advancing its stem cell and pharmaceutical inspection businesses. In 2023, the Group established Pingxiang Ganghua Dentistry Hospital Company Limited, reinforcing its strategic blueprint in the healthcare industry. Furthermore, the company has shown prudence in stabilizing its real estate segment by focusing on inventory reduction, urban redevelopment, and cautious investment strategies in alignment with national real estate policies. In the past 1-2 years, Sino Harbour has increased its focus on healthcare, particularly in stem cell technology, through strategic cooperation agreements with medical universities and hospitals, such as the Second Affiliated Hospital of Guilin Medical University. The group also continues to optimize its resource structure to reduce costs and stabilize growth amid market uncertainties. In late 2025, the chairman increased shareholding in the company, signaling confidence in the company’s future. The Group reported a revenue of approximately RMB 239.8 million in the first half of the 2025/26 fiscal year, with a focus on sustaining income streams both from property sales and its healthcare initiatives. Overall, Sino Harbour Holdings Group Limited operates primarily in property development and health-related businesses within mainland China, with notable emphasis on residential and commercial property development as well as pharmaceutical, stem cell, and dental services. It pursues a dual focus on stabilizing its real estate operations while aggressively cultivating the healthcare sector as a key growth driver. This comprehensive profile reflects Sino Harbour’s diversified business model and recent strategic shifts, including key healthcare sector initiatives and sustained real estate development focus, headquartered in Nanchang, China, founded 2011. Sources, , , , , .